Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BCRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BCRX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

BioCryst Pharmaceuticals Inc

BCRX
Current price
8.94 USD -0.08 USD (-0.89%)
Last closed 9.02 USD
ISIN US09058V1035
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 1 870 694 912 USD
Yield for 12 month +39.25 %
1Y
3Y
5Y
10Y
15Y
BCRX
21.11.2021 - 28.11.2021

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Address: 4505 Emperor Boulevard, Durham, NC, United States, 27703

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

17.33 USD

P/E Ratio

Dividend Yield

Financials BCRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BCRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+450 712 000 USD

Last Year

+331 412 000 USD

Current Quarter

+145 534 000 USD

Last Quarter

+131 534 000 USD

Current Year

+438 443 000 USD

Last Year

+325 096 000 USD

Current Quarter

+140 966 000 USD

Last Quarter

+125 403 000 USD
EBITDA 37 473 000 USD
Operating Margin TTM 14.59 %
Price to Earnings
Return On Assets TTM 4.54 %
PEG Ratio -0.28
Return On Equity TTM -1 925.37 %
Wall Street Target Price 17.33 USD
Revenue TTM 503 484 992 USD
Book Value -2.16 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 56.90 %
Dividend Yield
Gross Profit TTM 323 483 008 USD
Earnings per share -0.26 USD
Diluted Eps TTM -0.26 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -10.62 %

Stock Valuation BCRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 43.67
Enterprise Value Revenue 4.71
Price Sales TTM 3.72
Enterprise Value EBITDA 49.81
Price Book MRQ 56.59

Technical Indicators BCRX

For 52 Weeks

6.02 USD 11.31 USD
50 Day MA 9.96 USD
Shares Short Prior Month 24 024 642
200 Day MA 8.30 USD
Short Ratio 5.52
Shares Short 23 076 302
Short Percent 11.07 %